Immune checkpoint inhibitors (ICIs), such as programmed cell death protein-1 (PD-1)/PD-1 ligand (PD-L1) inhibitors, have changed the treatment landscapes of various malignant tumors, which constitute the present mainstay of systemic anti-cancer therapies along with cytotoxic agents and targeted agents (6). This evidence concerns the gene PDCD1 and cancer.